Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxazolidinone - TB Alliance

Next Previous
Drug Profile

Oxazolidinone - TB Alliance

Alternative Names: TBI-223

Latest Information Update: 20 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Global Alliance for TB Drug Development; Institute of Materia Medica
  • Developer Global Alliance for TB Drug Development
  • Class Antituberculars; Carbamates; Fluorobenzenes; Oxazolidinones; Small molecules; Spiro compounds
  • Mechanism of Action 23S ribosomal RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 20 Mar 2025 Phase-II clinical trials in Tuberculosis (PO), prior to March 2025 (TB Alliance pipeline, March 2025)
  • 04 Dec 2023 TBI 223 is still in phase I trials for Tuberculosis in the US (Global Alliance for TB Drug Development pipeline, December 2023)
  • 25 Mar 2022 Global Alliance completes a phase I trial in Tuberculosis (In volunteers) in the US (PO) (NCT04865536)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top